We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NBN:NASDAQNortheast Bank Analysis

Data as of 2026-04-19 - not real-time

$124.15

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Northeast Bank (NBN) is trading at a price well above its 20‑day (≈$116) and 50‑day (≈$115) SMAs, signaling a strong bullish momentum. The RSI sits near 68, indicating the stock is approaching overbought territory but still has room for upside. Technicals are reinforced by a bullish MACD histogram and a clear uptrend, while the 30‑day volatility of over 22% and a beta above 1 suggest heightened price swings. Fundamentally, the company trades at a forward P/E of under 9 versus an industry average of ~17.7, pointing to a substantial valuation discount. Operating margins exceed 60% and ROE is near 18%, underscoring efficient earnings generation despite a modest revenue contraction of 3.1%. The balance sheet shows ample cash (≈$446 M) relative to debt (≈$519 M) and a negligible payout ratio, making the 3% dividend highly sustainable. Analyst consensus is limited (2 analysts, no explicit recommendation), but the target price of $126.5 implies modest upside of roughly 2% from the current level. Overall, the stock blends strong technical support, attractive valuation, and a durable dividend, though the regional banking sector carries moderate regulatory and credit risk.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish technical positioning near key SMAs
  • RSI approaching overbought levels
  • Decreasing volume trend adds caution

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Significant valuation discount to peers
  • Strong operating margins and ROE
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable cash generation and solid balance sheet
  • Regional banking exposure to credit cycles
  • Consistent dividend yield supporting income investors

Key Metrics & Analysis

Financial Health

Revenue Growth-3.10%
Profit Margin40.91%
P/E Ratio12.0
ROE17.79%
ROA1.93%
P/B Ratio2.0
Op. Cash Flow$7.1M
Industry P/E17.7

Technical Analysis

TrendBullish
RSI68.4
Support$105.51
Resistance$127.00
MA 20$116.21
MA 50$114.85
MA 200$103.82
MACDBullish
VolumeDecreasing
Fear & Greed Index90.21

Valuation

Target Price$126.50
Upside/Downside1.89%
GradeUndervalued
TypeValue
Dividend Yield0.03%

Risk Assessment

Beta1.14
Volatility22.65%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.